Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenobarbital is a long-acting barbiturate used primarily as an anticonvulsant and sedative. It was first introduced in 1912 and remains one of the oldest antiepileptic drugs still in use. Phenobarbital acts by enhancing the activity of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system, leading to increased neuronal inhibition and reduced excitability. It is recommended by the World Health Organization for treating certain types of epilepsy—especially in developing countries—and is commonly used for neonatal seizures in developed countries. Other uses include management of insomnia, anxiety disorders, withdrawal from other barbiturates or benzodiazepines, preoperative sedation, and occasionally for status epilepticus when other treatments fail. Phenobarbital can be habit-forming with potential for abuse and withdrawal symptoms upon discontinuation[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenobarbital.